bms_nassau_park_new_jersey

CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL

pharmafile | December 17, 2018 | News story | Sales and Marketing |ย ย BMS, Bristol-Myers Squibb, Cancer, Sprycel, allย 

New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy for the treatment of paediatric patients (Ph+) acute lymphoblastic leukemia (ALL).

The powder form of Sprycel, which allows patients with an inability to swallow tablets to suspnd the medicines in water, was first approved by the European Commission in July 2018.

โ€œWe are pleased with todayโ€™s CHMP recommendation for Sprycel in pediatric patients with Ph+ ALL, and look forward to the possibility of expanding Sprycelโ€™s pediatric indications in the EU to include young patients with this particularly high-risk leukemia,โ€ said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb.

Advertisement

Louis Goss

Related Content

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโ€™s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europeโ€™s first XSeed Labs research project, …

T-cell therapy โ€“ the evolution of cancer treatments

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content